123 related articles for article (PubMed ID: 38508431)
21. High frequency of CD4+ CXCR5+ TFH cells in patients with immune-active chronic hepatitis B.
Feng J; Lu L; Hua C; Qin L; Zhao P; Wang J; Wang Y; Li W; Shi X; Jiang Y
PLoS One; 2011; 6(7):e21698. PubMed ID: 21750724
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B.
Farag MS; van Campenhout MJH; Pfefferkorn M; Fischer J; Deichsel D; Boonstra A; van Vuuren AJ; Ferenci P; Feld JJ; Berg T; Hansen BE; van Bömmel F; Janssen HLA
Clin Infect Dis; 2021 Jan; 72(2):202-211. PubMed ID: 31912157
[TBL] [Abstract][Full Text] [Related]
23. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
[TBL] [Abstract][Full Text] [Related]
24. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B.
Zhang C; Yang Z; Wang Z; Dou X; Sheng Q; Li Y; Han C; Ding Y
Int J Med Sci; 2020; 17(3):383-389. PubMed ID: 32132873
[No Abstract] [Full Text] [Related]
25. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
[TBL] [Abstract][Full Text] [Related]
26. Hepcidin expression levels involve efficacy of pegylated interferon-α treatment in hepatitis B-infected liver.
Jia J; Zhang Y; Zhang H; Chen Z; Chen L; Zhou Q; Lv X; Wang Q
Int Immunopharmacol; 2022 Jun; 107():108641. PubMed ID: 35217337
[TBL] [Abstract][Full Text] [Related]
27. Immune correlates of hepatitis B surface antigen spontaneous seroconversion in hepatitis B e antigen negative chronic hepatitis B patients.
Vyas AK; Sharma BC; Sarin SK; Trehanpati N
Liver Int; 2018 Jan; 38(1):38-49. PubMed ID: 28500636
[TBL] [Abstract][Full Text] [Related]
28. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
29. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
30. Clinical Efficacy of PEG-IFN
Jia N; Gao W; Fan X; Gao H; Li X; Mi B; Yang J
Oxid Med Cell Longev; 2022; 2022():3185320. PubMed ID: 35726331
[TBL] [Abstract][Full Text] [Related]
31. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study.
Zheng Z; Liao W; Liu L; Cai S; Zhu H; Yin S
Biomed Pharmacother; 2020 Feb; 122():109698. PubMed ID: 31918272
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of peg-interferon-nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB.
Xu W; Li Q; Huang C; Hu Q; Qi X; Huang Y; Zhang J; Chen L
Hepatol Int; 2021 Feb; 15(1):51-59. PubMed ID: 32990919
[TBL] [Abstract][Full Text] [Related]
33. IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients.
Galmozzi E; Facchetti F; Grossi G; Loglio A; Viganò M; Lunghi G; Colombo M; Lampertico P
Liver Int; 2018 Mar; 38(3):417-423. PubMed ID: 28732143
[TBL] [Abstract][Full Text] [Related]
34. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
[TBL] [Abstract][Full Text] [Related]
35. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
36. Expansion of circulating TFH cells and their associated molecules: involvement in the immune landscape in patients with chronic HBV infection.
Hu TT; Song XF; Lei Y; Hu HD; Ren H; Hu P
Virol J; 2014 Mar; 11():54. PubMed ID: 24655429
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.
Chuaypen N; Sriprapun M; Praianantathavorn K; Payungporn S; Wisedopas N; Poovorawan Y; Tangkijvanich P
J Med Virol; 2017 Jan; 89(1):130-138. PubMed ID: 27307409
[TBL] [Abstract][Full Text] [Related]
38. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.
Choi HSJ; Sonneveld MJ; Farag MS; Brouwer WP; Brakenhoff SM; Hirode G; Gehring AJ; de Man RA; Hansen BE; Janssen HLA
J Viral Hepat; 2021 Dec; 28(12):1729-1737. PubMed ID: 34514678
[TBL] [Abstract][Full Text] [Related]
39. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients.
Zhu MY; Chen PZ; Li J; Yu DM; Huang D; Zhu XJ; Han Y; Chen J; Huang W; Chen YY; Gong QM; Jiang JH; Zhang DH; Zhang Y; Zhang JM; Zhang XX
J Med Virol; 2018 Apr; 90(4):721-729. PubMed ID: 29247529
[TBL] [Abstract][Full Text] [Related]
40. Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients.
Zhou P; Yang F; Wang J; Mao R; Qi X; Huang Y; Zhang J
Medicine (Baltimore); 2015 May; 94(17):e730. PubMed ID: 25929904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]